Silence Therapeutics to Participate in September Investor Conferences

Rhea-AI Summary

Silence Therapeutics (AIM: SLN, Nasdaq: SLN) will participate in two virtual investor conferences in September 2021. The events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, featuring a fireside chat at 11:45am EDT, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, available on-demand starting at 7:00am EDT. Interested parties can access the webcasts through the Investors section of Silence's website, where archived replays will also be available.

Silence Therapeutics to Participate in September Investor Conferences

25 August 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will present at two virtual investor conferences in September, details of which can be found below:

Morgan Stanley 19^th Annual Global Healthcare Conference

Format: Fireside Chat

Date: Friday, September 10^th

Time: 11:45am EDT / 4:45pm BST

H.C. Wainwright 23^rd Annual Global Investment Conference

Format: Company Presentation

Date: Monday, September 13^th

Time: On-demand starting at 7:00am EDT / 12:00pm BST

Webcasts of the fireside chat and presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcasts will be available on the Company’s website following the conference.

Enquiries:

Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com	Tel:  +1 (646) 637-3208
Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence	Tel:  +44 (0) 20 7597 5970
European PR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com	Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

FAQ

What conferences will Silence Therapeutics participate in September 2021?

Silence Therapeutics will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

What is the format of the Morgan Stanley conference presentation?

The Morgan Stanley conference will feature a fireside chat format on September 10, 2021, at 11:45am EDT.

When will the H.C. Wainwright conference presentation be available?

The H.C. Wainwright conference presentation will be available on-demand starting at 7:00am EDT on September 13, 2021.

Where can I find the webcasts for Silence Therapeutics' conferences?

Webcasts for Silence Therapeutics' conferences can be accessed via the Investors section of their website, and archived replays will also be available afterward.

What is the significance of Silence Therapeutics' participation in these conferences?

Participation in these conferences allows Silence Therapeutics to showcase its developments in siRNA therapeutics and engage with potential investors, highlighting their ongoing projects.